Stroke is a leading cause of death and disability worldwide, and approximately 87% of
cases are attributed to ischemia. The main factors that cause ischemic stroke include …

Glucuronidation is a listed clearance mechanism for 1 in 10 of the top 200 prescribed drugs.
The objective of this article is to encourage those studying ligand interactions with UDP …

Offers essential guidance for discovering and optimizing novel drug therapies Using
detailed examples, Evaluation of Enzyme Inhibitors in Drug Discovery equips researchers …

Variability of drug metabolism, especially that of the most important phase I enzymes or
cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of …

Drug-drug interactions (DDIs) are a major cause of adverse drug effects and a public health
concern, as they increase hospital care expenses and reduce patients' quality of life. DDI …

Regulation of cosmetic testing and poor predictivity of preclinical drug studies has spurred
efforts to develop new methods for systemic toxicity. Current in vitro assays do not fully …

The measurement of the effect of new chemical entities on human cytochrome P450 marker
activities using in vitro experimentation represents an important experimental approach in …

Ethnicity is one factor that may account for the observed differences in both
pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, resulting in variability in …

This white paper addresses current approaches and knowledge gaps concerning methods
to assess the role of transport proteins in drug/metabolite disposition in humans. The …

Abstract Background Drug–drug interactions (DDIs) are responsible for many serious
adverse events; their detection is crucial for patient safety but is very challenging. Currently …